These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15548354)

  • 1. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
    Lopez-Barcons LA; Zhang J; Siriwitayawan G; Burke TG; Perez-Soler R
    Neoplasia; 2004; 6(5):457-67. PubMed ID: 15548354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ
    Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
    Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
    Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
    Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes.
    Daemen T; Dontje BH; Veninga A; Scherphof GL; Oosterhuis WL
    Sel Cancer Ther; 1990; 6(2):63-71. PubMed ID: 2367753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
    Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
    Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture).
    Kanaoka E; Takahashi K; Yoshikawa T; Jizomoto H; Nishihara Y; Uchida N; Maekawa R; Hirano K
    J Control Release; 2002 Aug; 82(2-3):183-7. PubMed ID: 12175736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
    Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
    Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.